Blueprint Medicines

Subsidiary of Sanofi (SNY)

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Approved
RETSmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
Pan-KRASSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
September 2029 (1)
BLU-924Phase 1/2Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Est. primary completion 2029-09 · NCT07629960 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

December 2025ApprovalPralsetinibFDA updates Boxed Warning on Pralsetinib (NDA213721)
US, FDA · FDA · Source ↗

Financial reports

No financial reports recorded.